Interní Med. 2003; 5(8): 389-393

Ovariální hyperstimulační syndrom - soubor interních komplikací u gynekologických pacientek

MUDr. Dan Marek Ph.D1, MUDr. Štěpán Machač2
1 I. interní klinika FN a LF UP Olomouc
2 Porodnicko-gynekologická klinika FN a LF UP Olomouc

Keywords: sterility, in vitro fertilization, ovarion hyperstimulatian syndrome.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marek D, Machač Š. Ovariální hyperstimulační syndrom - soubor interních komplikací u gynekologických pacientek. Interní Med. 2003;5(8):389-393.

Léčba sterility metodou in vitro fertilizace a embryotransferu je založena na stimulaci ovarií gonadotropiny, získání oocytů punkcí, oplodnění in vitro a přenosu embryí do dělohy. Hormonální stimulace však s sebou nese riziko tzv. ovariálního hyperstimulačního syndromu. Zatímco lehké formy mohou odeznít spontánně, při závažnější formě jde o potenciálně fatální komplikaci. Syndrom je v jednotlivých fázích charakterizován zvýšenou propustností kapilár, únikem tekutin do extravazálního prostoru, hemokoncentrací, hypovolemií, trombózami, cirkulačním šokem a terminálním selháním orgánů.

Autoři podávají stručný přehled patogenetických mechanizmů a možností léčby.

Ovarian hyperstimulation syndrome - range of internal complications in gynecologic patients treated by in vitro fertilization

In vitro fertilization and embryotransfer as a method of sterility treatment is based on ovarian stimulation by gonadotropins, obtaining of oocytes by puncture and transfer of embryo to uterus. Hormonal stimulation creates risk of ovarian hyperstimulation syndrome. While mild forms could resolve spontaneously, severe form could be a potentially fatal complication. Syndrome in its phases is characterized by increased vascular permeability with capillary leakage into extravasal space, hemoconcentration, hypovolemia, thromboses, circulation shock and terminal organ failure.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aboulghar M. Systemic effects of ovarian hyperstimulation syndrome: Implications for the rationale of treatment. Fertility and Sterility. Proceedings of the 15th World Congress on Fertility and Sterility. September 1995.
    2. Abramov Y, Barak V, Nisman B, et al. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997; 67: 261-264. Go to original source... Go to PubMed...
    3. Abramov Y, Schenker JG, Lewin A, et al. Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndome, Fertil Steril 2001; 76: 51-57. Go to original source... Go to PubMed...
    4. Balasch J, Arroyo V, Carmona F, et al. Severe ovarian hyperstimulation syndrome: role of peripheral vasodilatation. Fertil Steril 1991; 51: 1077-1083. Go to original source... Go to PubMed...
    5. Balasch J, Reverter JC, Fabregues F, et al. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Fertil Steril 1996; 66: 608-613. Go to original source... Go to PubMed...
    6. Bazzan M, Donvito V. Low-molecular-weight Heparin During Pregnancy, Thrombosis Research 2001; 101: 175-186. Go to original source... Go to PubMed...
    7. Borenstein R, Elchalal U, Lunenfeld B, et al. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 1989; 51: 791-95. Go to original source... Go to PubMed...
    8. Brinsden P, Wada I, Tan SL, et al. Diagnosis, prevention and managment of ovarian hyperstimulation syndrome. Brit J Obstet Gynaec 1995; 102: 767-772. Go to original source... Go to PubMed...
    9. Carcoana OV, Hines RL. Is renal dose dopamine protective or therapeutic? Yes. Crit Care Clin 1996; 12: 677-685. Go to original source... Go to PubMed...
    10. Delbaere A, Rodesch C, EnglertY. Update on ovarian hyperstimulation syndrome. Rev Med Brux Nov 1995; 16, 354-360 (abstrakt). Go to PubMed...
    11. Delvigne A, Demoulin A, Smitz J, et al. The ovarian hyperstimulation syndrome in in vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod 1993; 9: 1353-1360. Go to original source... Go to PubMed...
    12. Dostál J, Oborná I, Machač Š, Březinová J, Labanová M, Talaš M, Kudela M. Etické aspekty nových metod asistované reprodukce. Asistovaná reprodukce 2000; 10: 31-32.
    13. Dostál J. Ultrazvuk v léčbě sterility. In Doležal L (ed.). Ultrazvuk v gynekologii a porodnictví. Olomouc Univerzita Palackého 1998: 133-147.
    14. Dostál J, Oborná I, Talaš M, Chrastinová L, Kudela M. Využití kontracepce a podpůrné terapie kortikoidy v průběhu IVF+ET. Celostátní konference Reprodukční medicína. Brno 1998: 12s. Go to original source...
    15. Esposito MA, RL Van Nest, Sagoskin AW, et al. Outpatient management of ovarian hyperstimulation syndrome (OHSS) without the use of albumin, Fertil Steril 2002; 78 (Supl 1): S10-S11. Go to original source...
    16. Fukaya T, Chida S, Terada Y, et al. Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and reinfusion of ascitic fluid. Fertil Steril 1994; 61: 561-564. Go to original source... Go to PubMed...
    17. Gokmen O, Ugur M, Ekin M, et al. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur J Obst Gynecol Repr Biol 2001; 96: 187-192. Go to original source... Go to PubMed...
    18. Golan A, Ron-El A, Herman A, et al. Ovarian hyperstimulation syndrome - an update review. Obstet Gynecol Surv 1995; 44: 430-440. Go to original source... Go to PubMed...
    19. Goldsman MP, Pedram A, Dominques CE, et al. Increased capillary permeability induced by human folluicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 1995; 63: 268-272. Go to original source... Go to PubMed...
    20. Kamada S, Kubota T, Taguchi M, et al. High levels of immunoreactive endothelin-1 in human follicular fluids. Hum Reprod 1993; 8: 674-677. Go to original source... Go to PubMed...
    21. Katz Z, Lancet M, Borenstein R, et al. Absence of teratogenicity of indomethacin in ovarian hyperstimulation syndrome. Int J Fertil 1984; 29: 186-188. Go to PubMed...
    22. Manau D, Arroyo V, Jiménez W, et al. Chronology of hemodynamic changes in asymptomatic in vitro fertilization patients and relationship with ovarian steroids and cytokines. Fertil Steril 2002; 7: 1178-1183. Go to original source... Go to PubMed...
    23. Mardešič T. Hyperstimulační syndrom, klasifikace, patofyziologie, prevence a léčba. Čs gynekologie 1993; 58: 23-26.
    24. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Current Obstetrics and Gynaecology 2002; 12: 111-116. Go to original source...
    25. Mathur R, Hayman G, Bansal A, et al. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception. Fertil Steril 2002; 78: 1154-1158. Go to original source... Go to PubMed...
    26. Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 901-907. Go to original source... Go to PubMed...
    27. McClure N, Leya J, Radwanska E, et al. Luteal phase support and severe ovarian hyperstimulation syndrome. Hum Reprod 1992; 7: 758-764. Go to original source... Go to PubMed...
    28. Molskness TA, Patton TE, Martinez-Chequer JC, et al. Circulating vascular endothelial growth factor (VEGF) levels in nonhuman primates and women: species differences and relevance to ovarian hyperstimulation syndrome. Fertil Steril 2001; 76 (Supplement 1): S90-S91. Go to original source...
    29. Morris RS, Miller C, Jacobs L, et al. Conservative management of ovarian hyperstimulation syndrome. J Reprod Med 1995; 40: 711-714. Go to PubMed...
    30. Morris RS, Wong IL, Kirkman E, et al. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 1995; 10: 1355-1358. Go to original source... Go to PubMed...
    31. Navot D, Margalioth EJ, Laufer N, et al. Direct correlation between plasma renin activity and severity of ovarian hyperstimulation syndrome. Fertil Steril 1987; 48: 57-61. Go to original source... Go to PubMed...
    32. Orvieto R, Voliovitch I, Fishman P, et al. Interleukin-2 and ovarian hyperstimulation syndrome: A pilot study. Hum Reprod 1995;10: 24-27. Go to original source... Go to PubMed...
    33. Park W, Kim D, Ko D, et al. The effect angiotensin II and ACE inhibitor in ovarian hyperstimulation syndrome of rabbit, Fertil Steril 2002; 78: Supplement 1: S 223. Go to original source...
    34. Pride SM, Yuen BH, Moon YS, et al. Relationship of gonadotropin-releasing hormone, danasol and prostaglandin blockade to ovarian hyperstimulation syndrome in the rabbit. Am J Obstet Gynecol 1986; 154: 1155-1160. Go to original source... Go to PubMed...
    35. Rizk B, Aboulghar M, Smitz J, et al. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997; 3: 255-266. Go to original source... Go to PubMed...
    36. Schenker JG. Prevention and treatment of ovarian hyperstimulation. Hum Reprod 1993; 8: 653. Go to original source... Go to PubMed...
    37. Schenker JG. Clinical aspects of ovarian hyperstimulation syndrome. Eur J Obstetr Gynecol Repr Biol 1999; 85: 13-20. Go to original source... Go to PubMed...
    38. Schenker JG. Prevention and managements of ovarian hyperstimulation syndrome. In: Genazzani AR, Petraglia F, Volpe A, editors. Progress in gynecology and obstetrics. Parthenon Publishing Group 1990: 661-669.
    39. Sovová E, Oborná I, Dostál J, et al. Ovariální hyperstimulační syndrom s perikardiálním a pleurálním výpotkem komplikovaný supraventrikulární arytmií. Časopis lékařů českých 1999; 138: 730-733. Go to PubMed...
    40. Tarlatzis BC, Grimbizis G. Prevention of the ovarian hyperstimulation syndrome. Fertility and Sterility. Proceedings of the 15th World Congress on Fertility and Sterility, September 1995.
    41. Teruel MJG, Carbonell LF, Llanos MC, et al. Hemodynamic state and the role of angiotensin II in ovarian hyperstimulation syndrome in the rabbit. Fertil Steril 2002; 77: 1256-1260. Go to original source... Go to PubMed...
    42. Tutinen BC, Grimbizis G. Effect of cryoconservation in prevention of ovarian hyperstimulation syndrome. Brit J Obstet Gynaec 1995; 102: 326-329. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.